```
     FILE 'REGISTRY' ENTERED AT 09:41:45 ON 09 AUG 2007
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           67 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 09:42:34 ON 09 AUG 2007
L4           11 S L3/THU
L5            5 S L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'STNGUIDE' ENTERED AT 09:43:09 ON 09 AUG 2007
```

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:41:45 ON 09 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 AUG 2007 HIGHEST RN 944313-22-8
DICTIONARY FILE UPDATES: 8 AUG 2007 HIGHEST RN 944313-22-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10530088.str





chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
2-6 2-18 3-19 3-20 5-15 5-21 7-12 9-13 10-14 11-17 15-16 15-22 15-23

ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 2-6 3-4 4-5 6-7 6-11 7-8 7-12 8-9 9-10 9-13 10-11 15-16

exact bonds :

2-18 3-19 3-20 5-15 5-21 10-14 11-17 15-22 15-23

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:42:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d l2 scan

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Valine, N-[[[(2R,4R)-4-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-1,3-dioxolan-2-yl]methoxy][3-(hexadecyloxy)propoxy]phosphinyl]-, methyl ester (9CI)

MF C34 H62 N3 O10 P

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,4R)-2-[(acetyloxy)methyl]-1,3-dioxolan-4-yl]-5-methyl-, rel- (9CI)
MF C11 H14 N2 O6

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 09:42:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 228 TO ITERATE

100.0% PROCESSED 228 ITERATIONS 67 ANSWERS
SEARCH TIME: 00.00.01

L3 67 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 09:42:34 ON 09 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 Aug 2007 VOL 147 ISS 7
FILE LAST UPDATED: 8 Aug 2007 (20070808/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3/thu
            32 L3
        922172 THU/RL
L4          11 L3/THU
                (L3 (L) THU/RL)

=> s l4 and (PY<2003 or AY<2003 or PRY<2003)
      22880502 PY<2003
       4449859 AY<2003
       3928395 PRY<2003
L5           5 L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d l5 1-5 ti abs bib
```

L5 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV
GI



I

AB The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate,

triphosphate or phosphodiester group, for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably, compds. according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition of thymidine kinase (TK). These agents include those selected from among nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, among others. These agents are generally selected from the group consisting of 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddI (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-D4FC, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV (Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fuseon and mixts. thereof. The TK dependent agents, such as AZT and D4T, may be used in combination with one of the dioloxane thymine compds. according to the present invention, but the use of such agents may be less preferred. In preferred compns. according to the present invention, R1 is preferably H or a C2-C18 acyl group or a monophosphate group. Pharmaceutical compns. and methods of reducing the likelihood that a patient at risk for contract an HIV infection will contract the infection are other aspects of the present invention.

AN 2004:513490 CAPLUS <<LOGINID::20070809>>
DN 141:65057
TI Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV
IN Chu, Chung K.; Schinazi, Raymond F.
PA The University of Georgia Research Foundation, Inc., USA; Emory University
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052296	A2	20040624	WO 2003-US39029	20031208 <--
	WO 2004052296	A3	20040923		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502625	A1	20040624	CA 2003-2502625	20031208 <--
	AU 2003296360	A1	20040630	AU 2003-296360	20031208 <--
	EP 1569659	A2	20050907	EP 2003-812874	20031208 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003017113	A	20051025	BR 2003-17113	20031208 <--
	CN 1723025	A	20060118	CN 2003-80105479	20031208 <--
	US 2005209196	A1	20050922	US 2005-530088	20050401 <--
	MX 2005PA03637	A	20050816	MX 2005-PA3637	20050405 <--
	IN 2005KN00698	A	20060224	IN 2005-KN698	20050421 <--
PRAI	US 2002-431812P	P	20021209 <--		
	WO 2003-US39029	W	20031208		

OS MARPAT 141:65057

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Method for the treatment or prevention of Flaviviridae viral infection using nucleoside analogs

AB A method is provided for treating or preventing a Flaviviridae viral infection in a host comprising administering a therapeutically effective amount of at least one nucleoside analog (Markush included). Preparation of nucleoside analogs is described.

AN 2001:338330 CAPLUS <<LOGINID::20070809>>

DN 134:348243

TI Method for the treatment or prevention of Flaviviridae viral infection using nucleoside analogs

IN Storer, Richard

PA Biochem Pharma Inc., Can.

SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032153	A2	20010510	WO 2000-CA1316	20001103 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2389745	A1	20010510	CA 2000-2389745	20001103 <--
	EP 1225899	A2	20020731	EP 2000-974218	20001103 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 6566365	B1	20030520	US 2000-704832	20001103 <--
	US 2003225037	A1	20031204	US 2003-397167	20030327 <--
PRAI	US 1999-163394P	P	19991104 <--		
	US 1999-163405P	P	19991104 <--		
	US 2000-704832	A3	20001103 <--		
	WO 2000-CA1316	W	20001103 <--		

OS MARPAT 134:348243

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of enantiomerically pure β-D-dioxolane nucleosides as virucides

GI



I

AB A method and composition for the treatment of humans infected with HIV that includes the administration of an HIV treatment amount of an enantiomerically pure β-D-dioxolanyl purine nucleosides I wherein R is OH, Cl, NH2, or H, or a pharmaceutically acceptable salt or derivative of the compound, optionally in a pharmaceutically acceptable carrier or diluent. Thus, I (R = OH) was prepared and tested in human peripheral blood mononuclear cells for its antiviral activity (EC50 = 0.03μM). The toxicity of the compds. were evaluated in uninfected human PBM cells and showed no toxicity at a concentration of 100 μM.

AN 1999:450894 CAPLUS <<LOGINID::20070809>>
DN 131:88137

TI Preparation of enantiomerically pure β-D-dioxolane nucleosides as virucides

IN Chu, Chung K.
PA Emory University, USA

SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5925643	A	19990720	US 1992-935515	19920825 <--
	US 5179104	A	19930112	US 1990-622762	19901205 <--
	CA 2099589	A1	19920606	CA 1991-2099589	19911205 <--
	EP 1164133	A2	20011219	EP 2001-203571	19911205 <--
	EP 1164133	A3	20020102		
	EP 1164133	B1	20070801		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	EP 1600448	A2	20051130	EP 2005-75365	19911205 <--
	EP 1600448	A3	20060823		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	EP 1693373	A1	20060823	EP 2005-77620	19911205 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC				
	US 5444063	A	19950822	US 1992-967460	19921028 <--
	WO 9404154	A1	19940303	WO 1993-US8044	19930825 <--
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9350933	A	19940315	AU 1993-50933	19930825 <--
	AU 670637	B2	19960725		
	EP 656778	A1	19950614	EP 1993-920366	19930825 <--
	EP 656778	B1	20010530		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08501086	T	19960206	JP 1994-506616	19930825 <--
	JP 3519736	B2	20040419		
	EP 1081148	A2	20010307	EP 2000-203932	19930825 <--
	EP 1081148	A3	20030305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, RO				
	ES 2157929	T3	20010901	ES 1993-920366	19930825 <--
	PT 656778	T	20010928	PT 1993-920366	19930825 <--
	JP 2002114787	A	20020416	JP 2001-251947	19930825 <--
	CA 2143107	C	20041123	CA 1993-2143107	19930825 <--
	US 5684010	A	19971104	US 1995-471533	19950606 <--
	US 5767122	A	19980616	US 1995-469465	19950606 <--
	AU 9716640	A	19970717	AU 1997-16640	19970327 <--
	AU 714646	B2	20000106		
	US 5830898	A	19981103	US 1997-838072	19970415 <--
	US 5834474	A	19981110	US 1997-839713	19970415 <--
	JP 2001097973	A	20010410	JP 2000-246125	20000815 <--
	JP 3881165	B2	20070214		
	GR 3036393	T3	20011130	GR 2001-401249	20010814 <--
	AU 2003200421	A1	20030410	AU 2003-200421	20030207 <--
	JP 2004149543	A	20040527	JP 2003-414876	20031212 <--

	JP 2007008959	A	20070118	JP 2006-263009	20060927 <--
PRAI	US 1990-622762	A2	19901205 <--		
	EP 1992-902800	A3	19911205 <--		
	EP 2001-203571	A3	19911205 <--		
	JP 1992-502956	A3	19911205 <--		
	US 1992-935515	B2	19920825 <--		
	US 1992-967460	A3	19921028 <--		
	AU 1993-50933	A3	19930825 <--		
	EP 1993-920366	A3	19930825 <--		
	JP 1994-506616	A3	19930825 <--		
	WO 1993-US8044	W	19930825 <--		
	US 1995-471533	A3	19950606 <--		
	JP 2000-246125	A3	20000815 <--		

OS MARPAT 131:88137
RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of antiviral 1,3-dioxolane nucleoside analogs
AB This invention includes the compds. 2'-deoxy-5-fluoro-3'-oxacytidines and pharmaceutically acceptable salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection (EC50 = 0.013-0.027 μM) with cytotoxicity of (IC50 < 1 μM).
AN 1999:17124 CAPLUS <<LOGINID::20070809>>
DN 130:66736
TI Preparation of antiviral 1,3-dioxolane nucleoside analogs
IN Liotta, Dennis C.; Schinazi, Raymond F.; Choi, Woo-baeg
PA Emory University, USA
SO U.S., 16 pp., Cont.-in-part of U.S. 5,210,085.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5852027	A	19981222	US 1993-150012	19931109 <--
	US 5210085	A	19930511	US 1991-659760	19910222 <--
	US 5276151	A	19940104	US 1991-803028	19911206 <--
	WO 9214729	A1	19920903	WO 1992-US1393	19920221 <--
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	AU 715577	B3	20000203	AU 1999-59571	19991119 <--
	AU 2002300661	A1	20030220	AU 2002-300661	20020820 <--
PRAI	US 1991-659760	A2	19910222 <--		
	US 1991-736089	B2	19910726 <--		
	US 1991-803028	A2	19911206 <--		
	WO 1992-US1393	W	19920221 <--		
	US 1990-473318	A2	19900201 <--		
	US 1993-15992	A	19930210 <--		
	AU 1999-44745	A3	19990826 <--		

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis and antiviral activity of 2'-deoxy-5-fluoro-3'-thiacytidine and nucleoside analogs
AB The present invention relates to a method of preparing the antiviral compds. 2'-deoxy-5-fluoro-3'-thiacytidine (FTC) and various prodrug analogs of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compds., particularly in the prevention and treatment of AIDS; and the compds. themselves. This synthetic route allows the stereoselective preparation of the biol. active isomer of these compds. and related compds. Thus, 2'-deoxy-5-fluoro-3'-thiacytidine was prepared and showed anti-HIV activity (EC50 = 0.011 μM) and cytotoxicity

(IC50 > 100 μM) in human PBM cells.

AN 1998:15591 CAPLUS <<LOGINID::20070809>>

DN 128:75640

TI Synthesis and antiviral activity of 2'-deoxy-5-fluoro-3'-thiacytidine and nucleoside analogs

IN Liotta, Dennis C.; Schinazi, Raymond F.; Choi, Woo-baeg

PA Emory University, USA

SO U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 402,730.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5700937	A	19971223	US 1995-481556	19950607	<--
	US 5204466	A	19930420	US 1990-473318	19900201	<--
	CA 2481078	A1	19910808	CA 1991-2481078	19910131	<--
	EP 872237	A1	19981021	EP 1998-201737	19910131	<--
	EP 872237	B1	20070117			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	JP 2001019690	A	20010123	JP 2000-160358	19910131	<--
	JP 2002012591	A	20020115	JP 2001-151618	19910131	<--
	JP 3530150	B2	20040524			
	EP 1772151	A2	20070411	EP 2006-77328	19910131	<--
	EP 1772151	A3	20070613			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	US 5210085	A	19930511	US 1991-659760	19910222	<--
	US 6703396	B1	20040309	US 1995-402730	19950313	<--
	US 5914400	A	19990622	US 1995-472345	19950607	<--
	US 6153751	A	20001128	US 1999-337910	19990622	<--
	AU 9944745	A	19991111	AU 1999-44745	19990826	<--
	AU 715577	B3	20000203	AU 1999-59571	19991119	<--
	JP 2001352997	A	20011225	JP 2001-151617	20010521	<--
	JP 3844978	B2	20061115			
	AU 2002300661	A1	20030220	AU 2002-300661	20020820	<--
	JP 2005053893	A	20050303	JP 2004-146115	20040517	<--
	JP 2006141408	A	20060608	JP 2006-33782	20060210	<--
	AU 2006207874	A1	20060928	AU 2006-207874	20060907	<--
PRAI	US 1990-473318	A2	19900201	<--		
	US 1991-659760	A2	19910222	<--		
	US 1991-736089	B1	19910726	<--		
	US 1993-92248	B1	19930715	<--		
	US 1995-402730	A2	19950313	<--		
	AU 1991-73004	A3	19910131	<--		
	CA 1991-2075189	A3	19910131	<--		
	EP 1991-904454	A3	19910131	<--		
	EP 1998-201737	A3	19910131	<--		
	JP 1991-504897	A3	19910131	<--		
	GB 1991-4741	A	19910306	<--		
	GB 1991-9505	A	19910502	<--		
	US 1993-15992	A1	19930210	<--		
	US 1994-215498	B1	19940321	<--		
	US 1995-472345	A1	19950607	<--		
	AU 1999-44745	A3	19990826	<--		
	JP 2001-151617	A3	20010521	<--		
	AU 2002-300661	A3	20020820	<--		